Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire.

摘要: Abstract Outcomes after umbilical cord blood transplantation (UCBT) for chronic lymphocytic leukemia (CLL)/small lymphoma (SLL) are unknown. We analyzed outcomes of 68 patients with poor-risk CLL/SLL who underwent reduced-intensity (RIC) UCBT from 2004 to 2012. The median age was 57 years and follow-up 36 months; 17 had del 17p/p53mutation, 19 fludarabine-refractory disease, 11 relapsed autologous stem cell transplantation, 8 diagnosis prolymphocytic leukemia, 4 Richter syndrome, progressive or refractory disease. most common RIC used cyclophosphamide, fludarabine, total body irradiation (TBI) in 82%; 15 patients received antithymocyte globulin. Most the grafts were HLA mismatched 76% a double UCBT. Median nucleated cells collected 4.7 × 107/kg. cumulative incidences (CI) neutrophil platelet engraftment 84% 72% at 60 180 days respectively; day 100 graft-versus-host disease (GVHD) (grade II IV) 43% 3-year GVHD 32%. CI relapse, nonrelapse mortality, overall survival, progression-free survival (PFS) 3 16%, 39%, 54%, 45%, respectively. Fludarabine-sensitive use low-dose TBI regimens associated acceptable PFS. In conclusion, RIC-UCBT seems be feasible improved observed fludarabine-sensitive regimens.